[1]
|
World Health Organization, “Pneumococcal Conjugate Vaccine for Childhood Immunization,” 2007.
http://www.who.int/wer/2007/wer8212
|
[2]
|
L. Ferro, et al., “Pneumococcal Conjugate Vaccine Impact against Invasive Disease Caused by Streptococcus pneumoniae,” Brazilian Journal of Pediatrics, Vol. 82, No. 3, 2006, pp. S67-S74.
|
[3]
|
G. Vespa, D. O. Constela, C. Pepe, M. A. Safadi, E. Berezin, et al., “Estimating the Cost Effectiveness of Pneumococcal Conjugate Vaccination in Brazil,” Pan American Journal of Public Health, Vol. 26, No. 6, 2009, pp. 518-28. doi:10.1590/S1020-49892009001200007
|
[4]
|
D. Constela, “Evaluating the Costs of Pneumococcal Disease in Selected Latin American Coutries,” Revista Panamericana de Salud Pública, Vol. 22, No. 4, 2007, pp. 268-278.
|
[5]
|
Center of Disease Control and Prevention, “Invasive Pneumococcal Disease in Young Children before Licensure of 13-Valent Pneumococcal Conjugate Vaccine— United States, 2007,” Morbity and Mortality Weekly Report, Vol. 59, No. 9, 2010, pp. 253-257.
|
[6]
|
S. I. Pelton, H. Huot, J. A. Finkelstein, et al., “Emergence of 19A as Virulent and Multidrug Resistant Pneumococcus in Massachusets Following Universal Immunization of Infants with Pneumococcal Conjugate Vaccine,” The Pediatric Infectious Disease Journal, Vol. 26, No. 6, 2007, pp. 468-472. doi:10.1097/INF.0b013e31803df9ca
|
[7]
|
Centers for Disease Control and Prevention, “Emergence of antimicrobial-resistant serotype 19A Streptococcus pneumoniae—Massachusetts. 2001-2006,” Morbity and Mortality Weekly Report, Vol. 56, No. 41, 2007, pp. 1077-1080.
|
[8]
|
T. Pilishvili, C. Lexau, M. M. Farley, et al., “Sustained Reductions in Invasive Pneumococcal Disease in the Era of Conjugate Vaccine,” The Journal of Infectious Diseases, Vol. 201, No. 1, 2010, pp. 32-41.
doi:10.1086/648593
|
[9]
|
E. C. Dinleyici and Z. A. Yargic, “Current Knowledge Regarding the Investigational 13-Valent Pneumococcal conjugate Vaccine,” Expert Review of Vaccines, Vol. 8, No. 8, 2009, pp. 977-986. doi:10.1586/erv.09.68
|
[10]
|
Food and Drug Administration (FDA), “Vaccines: Approved Products. Prevnar 13 (Pneumococcal 13-Valent Conjugate Vaccine),” 2010.
http://www.fda.gov/biologicsbloodvaccines/vaccines/approvedproducts/ucm201667.htm
|
[11]
|
Pfizer? and Wyeth?. “Pneumococcal 13-Valent Conjugate Vaccine Monography Product (“Prevenar 13”),” Brazilian Ministery of Healthy, 2010.
|
[12]
|
A. G. Dean and K. M. Sullivan, “OpenEpi Collection of Epidemiologic Calculators,” Version 2.3, 2009.
http://www.openepi.com/OE2.3/Menu/OpenEpiMenu.htm
|
[13]
|
K. A. Bryant, S. L. Block, S. A. Baker, et al., “Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine,” Pediatrics, Vol. 125, No. 5, 2010, p. 866-875.
|
[14]
|
S. T. Duggan, “Pneumococcal Polysaccharide conjugate vaccine (13-Valent, Adsorbed) [PREVENAR 13?],” Drugs, Vol. 70, No. 15, 2010, pp. 1973-1986.
doi:10.2165/11205110-000000000-00000
|
[15]
|
M. D. Snape, C. L. Klinger, E.D. Daniels, et al., “Immunogenicity and Reactogenicity of a 13-Valent Pneumococcal Conjugate Vaccine Administered at 2, 4 and 12 Months of Age,” The Pediatric Infectious Disease Journal, Vol. 29, No. 12, 2010, pp. e80-e90.
doi:10.1097/INF.0b013e3181faa6be
|
[16]
|
O. G. Vanderkooi, D. W. Scheifele, D. Girgenti, et al., “Safety and Immunogenicity of a 13-Valent Pneumococcal Conjugate Vaccine in Healthy Infants and Toddlers Given with Routine Pediatric Vaccinations in Canada,” The Pediatric Infectious Disease Journal, Vol. 31, No. 1, 2012, pp. 72-77. doi:10.1097/INF.0b013e318233049d
|